StockData

uniQure vs Scynexis

QURE and SCYX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How QURE and SCYX compare

uniQure is the larger company, worth 51 times as much as Scynexis ($1.4B against $28.4M).

Scynexis grew revenue faster over the last twelve months (490% versus 30.2% for uniQure).

Scynexis keeps more of each dollar of sales as profit, with a net margin of −53.3% compared with −1351% at uniQure.

Scynexis scores higher on the StockData Score (13 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricQURESCYX
Size and price
Market cap$1.4B$28.4M
Share price$20.78$2.85
Change, 1 year−30.5%−39.2%
Change, 5 years−27.9%−95.2%
Beta (5Y)3.141.58
Employees22118
StockData Score
Total score413 (better)
Valuation score03 (better)
Growth score22
Performance score03 (better)
Health score25 (better)
Dividend score00
Valuation
P/S77.2×1.5× (better)
P/B4.4×0.4× (better)
FCF yield−11.2%–
Fair value$6.42$10.05
Margin of safety−224%71.6% (better)
Growth
Revenue growth (TTM)30.2%490% (better)
Revenue growth, 5Y average−15.6%–
Profitability
Gross margin92.5%–
Operating margin−1072%−118% (better)
Net margin−1351%−53.3% (better)
FCF margin−865%–
Return on equity−158%−18.4% (better)
Financial health
Debt / equity0.15 (better)0.00
Interest coverage−3.4×–
Current ratio10.01 (better)9.65
Altman Z-score−0.51 (better)−5.27
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions96.0%51.7%
Held by insiders2.1%24.8%
Insider net buying, 12 months−$20.2M–
Short interest, % of float12.5%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.